22 completed, 14 unknown, 6 recruiting, 2 active not recruiting. 47 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 47 | Completed 22, Unknown 14, Recruiting 6, Active not recruiting 2, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
Follow Leukemia, Myeloid, Acute: new trials by email Literature Review of Leukemia, Myeloid, Acute trials Research Report on Leukemia, Myeloid, Acute
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates - AML (Acute Myeloid Leukemia), Glioma | Phase 4 | Recruiting | Rigel Pharmaceuticals | 16 | 2026-02-23 | 2026-08-11 |
| Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 4 | Recruiting | AbbVie | 100 | 2025-07-24 | 2026-09-11 |
| Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies Ceftazidime, Ciprofloxacin - Neutropenic Fever, Acute Lymphoblastic Leukemia | Phase 4 | Recruiting | Gadjah Mada University | 120 | 2025-06-01 | 2025-08-22 |
| CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML Cladribine, Cytarabine, G-CSF - Relapsed/Refractory AML | Phase 4 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 172 | 2025-02-01 | 2025-01-08 |
| Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality Oral Azacitidine - Acute Myeloid Leukemia | Phase 4 | Recruiting | Virginia Commonwealth University | 12 | 2024-11-07 | 2026-11-05 |
| Antimicrobial Revision in Persistent Febrile Neutropenia Meropenem, Micafungin - Febrile Neutropenia | Phase 4 | Withdrawn | Wake Forest University Health Sciences | 2024-08-01 | 2024-09-19 | |
| RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR Venetoclax, Allogeneic transplant - Acute Myeloid Leukemia | Phase 4 | Recruiting | He Huang | 118 | 2024-07-17 | 2024-08-26 |
| Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive Chemotherapy Venetoclax, Azacitidine, Decitabine - Acute Myeloid Leukemia | Phase 4 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 24 | 2022-06-01 | 2026-08-21 |
| Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3). daunomycin/Idarubicin+ Silybinin, daunomycin/Idarubicin - Acute Myeloid Leukemia, Newly Diagnosed | Phase 4 | Recruiting | Fujian Medical University Union Hospital | 100 | 2022-04-01 | 2026-05-01 |
| Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China Venetoclax, Azacitidine - Acute Myeloid Leukemia (AML) | Phase 4 | Active not recruiting | AbbVie | 44 | 2022-01-06 | 2025-08-12 |
| Ikervis for DED Due to GVHD Post Allo-HSCT Cyclosporine Ophthalmic - Leukemia (Both ALL and AML), MDS-EB-1 | Phase 4 | Unknown | Singapore Eye Research Institute | 40 | 2019-11-28 | 2020-11-19 |
| Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy Azacytidine, HAG Regimen, Azacytidine - Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia | Phase 4 | Unknown | Shenzhen Second People's Hospital | 114 | 2019-09-01 | 2022-03-15 |
| Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia Outpatient Care Model, CPX-351 - Leukemia, Myeloid, Acute | Phase 4 | Terminated | Medical College of Wisconsin | 3 | 2019-08-28 | 2022-07-19 |
| Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML Fludarabine, Cytarabine - Acute Myeloid Leukemia, Core-Binding Factor | Phase 4 | Completed | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 68 | 2017-01-01 | 2024-10-01 |
| Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) Decitabine, Daunorubicin, Cytarabine, Mitoxantrone, Cytarabine - Acute Myeloid Leukemia | Phase 4 | Unknown | The First Hospital of Jilin University | 180 | 2017-01-01 | 2017-01-20 |
| King's Invasive Aspergillosis Study II Posaconazole - Aplastic Anemia, Leukemia, Myeloid, Acute | Phase 4 | Completed | King's College Hospital NHS Trust | 120 | 2016-12-07 | 2020-04-02 |
| G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor GM-CSF, G-CSF, GM-CSF and G-CSF - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 4 | Unknown | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 405 | 2016-09-27 | 2018-10-17 |
| CINC424A2X01B Rollover Protocol ruxolitinib, panobinostat - Primary Myelofibrosis, Polycythemia Vera | Phase 4 | Active not recruiting | Novartis Pharmaceuticals | 279 | 2015-03-05 | 2026-10-19 |
| A Rollover Study to Provide Continued Treatment With Eltrombopag Eltrombopag (ELT) - Thrombocytopaenia | Phase 4 | Completed | Novartis Pharmaceuticals | 22 | 2013-10-15 | 2022-12-30 |
| Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Interferon-alpha - Acute Myeloid Leukemia | Phase 4 | Unknown | Peking University People's Hospital | 40 | 2013-10-01 | 2016-09-29 |
Showing 20 of 47. Sign in to see all of them.
Leukemia (7) · Leukemia, Promyelocytic, Acute (7) · Myelodysplastic Syndromes (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Recurrence (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Esophageal Neoplasms (2) · Febrile Neutropenia (2) · Graft vs Host Disease (2) · Head and Neck Neoplasms (2) · Hypopharyngeal Neoplasms (2) · Kidney Neoplasms (2)
Hematologic Diseases (47) · Hemic and Lymphatic Diseases (47) · Leukemia, Myeloid (47) · Neoplasms by Histologic Type (47) · Neoplasms (46) · Leukemia (40) · Bone Marrow Diseases (7) · Immune System Diseases (6) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Cytopenia (4) · Immunoproliferative Disorders (4) · Leukemia, Lymphoid (4) · Lymphatic Diseases (4)
Cytarabine (13) · Idarubicin (9) · Azacitidine (5) · fludarabine (5) · venetoclax (5) · Granulocyte Colony-Stimulating Factor (4) · Arsenic Trioxide (3) · Daunorubicin (3) · Decitabine (3) · Mitoxantrone (3) · posaconazole (3) · Filgrastim (2) · Gemtuzumab (2) · Micafungin (2) · fludarabine phosphate (2)
PETHEMA Foundation (7) · Technische Universität Dresden (4) · AbbVie (2) · Novartis Pharmaceuticals (2) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Centre Hospitalier Universitaire, Amiens (1) · Changhai Hospital (1) · Cytovia, Inc. (1) · Fox Chase Cancer Center (1) · Fujian Medical University Union Hospital (1) · Gadjah Mada University (1) · German AML Cooperative Group (1) · Guangdong Provincial People's Hospital (1) · He Huang (1)
China (14) · Spain (8) · Germany (7) · United States (7) · France (3) · Poland (3) · Belgium (2) · Greece (2) · India (2) · Russia (2) · South Korea (2) · Sweden (2) · Australia (1) · Bangladesh (1) · Bulgaria (1)
Sanz Miguel Angel, Dr (4) · Gerhard Ehninger, MD (3) · Xianmin Song, Doctor (2) · Barry R. Meisenberg, MD (1) · Bueno Javier, Dr (1) · Esteve Jordi, Dr (1) · Eva Lengfelder, MD, PhD (1) · Fang Yongjun, Ph.D (1) · Gao Fei, Ph.D (1) · Genovefa Papanicolaou, MD (1) · Guopan Yu (1)
PMID 36064577, PMID 24923295, PMID 28945881, PMID 10231138, PMID 10583235, PMID 12627513, PMID 15770833, PMID 16110027, PMID 16197446, PMID 18056840, PMID 18398750, PMID 19822296, PMID 20393132, PMID 20442365, PMID 20542125, PMID 20625136, PMID 21148082, PMID 21266057, PMID 21775497, PMID 22197676, PMID 22241828, PMID 22290953, PMID 22318524, PMID 22512017, PMID 22871557, PMID 22965967, PMID 23317527, PMID 23376821, PMID 23630210, PMID 23733379, PMID 24117042, PMID 25314773, PMID 25528350, PMID 25547501, PMID 25975975, PMID 26863635, PMID 28235771, PMID 28529313, PMID 28584252, PMID 28721449, PMID 29250743, PMID 30076280, PMID 30315349, PMID 31554370, PMID 32537166, PMID 32687450, PMID 32786187, PMID 33300144, PMID 33495363, PMID 34367728
2014 (1), R01CA091912 (1)